![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, September 14, 2010 6:37:26 AM
http://www.apricusbio.com/media_09142010.html
Rodman & Renshaw Annual Global Investment Conference NYC
SAN DIEGO-- (BUSINESS WIRE)-- Apricus Bio, Inc. (Nasdaq: APRI), backed by a revenue generating CRO business and seeking to leverage its proprietary, multi-route NexACT® drug delivery technology and internal pipeline through out-licensing arrangements and partnerships, today announced that Dr. Bassam Damaj, President and Chief Executive Officer, will present at the Rodman & Renshaw 12th Annual Healthcare Conference at 10:25am ET on Tuesday, September 14, 2010, in the Winslow Salon on the 5th floor of the New York Palace Hotel in New York City.
The Company's presentation will be available via webcast and can be accessed at: http://www.wsw.com/webcast/rrshq18/nexm.
About Apricus Bio, Inc.
Backed by a solid, revenue generating CRO business, Apricus Bio has leveraged the flexibility of its proven NexACT® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. Future growth will be driven primarily through out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies, worldwide. Concurrently, the Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. For further information on Apricus Bio and its subsidiaries, visit the following websites: www.apricusbio.com and www.bio-quant.com.
Apricus Bio Contacts:
Apricus Bio Investor Relations:
Paula Schwartz
Apricus Bio, Inc. Rx Communications Group, LLC
(917) 322-2216
pschwartz@rxir.com
Apricus Bio, Inc.
Edward Cox, V.P.
Investor Relations & Corporate Development Apricus Bio, Inc.
(858) 926-5811
ecox@ApricusBio.com
Recent SEEL News
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 06/14/2024 08:06:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:05:35 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 05/31/2024 08:30:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 08:01:36 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/20/2024 08:16:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/16/2024 01:00:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 03:45:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 12:00:41 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 03/06/2024 10:32:04 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/06/2024 09:50:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:39:18 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/06/2024 10:26:45 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 02/02/2024 11:04:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 09:01:23 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/30/2024 11:05:53 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:05:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 02:47:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 02:47:06 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 09:16:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 02:46:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 02:45:51 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 02:45:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 02:45:13 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/02/2024 01:10:24 PM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM